Considering the promising cardiorenal outcomes of GLP-1 RA in patients with T2DM and cardiovascular diseases, a great cardioprotective potential could be assessed in cancer patients treated with cardiotoxic therapies. The gene discussed is GCG; the disease is type 2 diabetes mellitus.